CCR2 receptor antagonists and uses thereof

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9670222
SERIAL NO

14260552

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • CENTREXION THERAPEUTICS CORPORATION

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Ebel, Heiner Biberach an der Riss, DE 21 281
Frattini, Sara Castelleone, IT 42 351
Gerlach, Kai Mittelbiberach, DE 55 264
Giovannini, Riccardo Verona, IT 83 626
Hoenke, Christoph Biberach an der Riss, DE 86 855
Mazzaferro, Rocco San Giuliano, IT 22 146
Santagostino, Marco Mittelbiberach, DE 49 334
Scheuerer, Stefan Warthausen, DE 32 308
Tautermann, Christofer Biberach, DE 6 69
Trieselmann, Thomas Mettenberg, DE 32 286

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Dec 6, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00